Vontobel Holding Ltd. Has $450,000 Holdings in Masimo Co. (NASDAQ:MASI)

Vontobel Holding Ltd. lessened its position in Masimo Co. (NASDAQ:MASI) by 41.1% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 3,838 shares of the medical equipment provider’s stock after selling 2,679 shares during the period. Vontobel Holding Ltd.’s holdings in Masimo were worth $450,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in MASI. Massachusetts Financial Services Co. MA bought a new position in shares of Masimo in the third quarter valued at approximately $132,699,000. Eminence Capital LP bought a new position in shares of Masimo in the third quarter valued at approximately $90,859,000. Hawk Ridge Capital Management LP lifted its holdings in shares of Masimo by 124.4% in the third quarter. Hawk Ridge Capital Management LP now owns 567,765 shares of the medical equipment provider’s stock valued at $49,782,000 after purchasing an additional 314,763 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. lifted its holdings in shares of Masimo by 2.1% in the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 413,815 shares of the medical equipment provider’s stock valued at $48,503,000 after purchasing an additional 8,498 shares in the last quarter. Finally, Sei Investments Co. lifted its holdings in shares of Masimo by 224.5% in the third quarter. Sei Investments Co. now owns 183,940 shares of the medical equipment provider’s stock valued at $16,128,000 after purchasing an additional 127,249 shares in the last quarter. Institutional investors and hedge funds own 85.96% of the company’s stock.

Analysts Set New Price Targets

MASI has been the topic of a number of recent analyst reports. StockNews.com upgraded Masimo from a “sell” rating to a “hold” rating in a report on Friday, March 29th. Wells Fargo & Company upgraded Masimo from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $117.00 to $160.00 in a report on Monday, March 25th. Needham & Company LLC lowered Masimo from a “buy” rating to a “hold” rating in a report on Wednesday, January 3rd. Jefferies Financial Group reiterated a “hold” rating and set a $121.00 price target (up from $107.00) on shares of Masimo in a report on Tuesday, January 30th. Finally, BTIG Research lifted their price target on Masimo from $145.00 to $166.00 and gave the stock a “buy” rating in a report on Monday, March 25th. Five analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $137.43.

Masimo Stock Down 0.3 %

Shares of NASDAQ:MASI opened at $134.32 on Tuesday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.22 and a current ratio of 2.18. The firm has a market capitalization of $7.11 billion, a P/E ratio of 88.95 and a beta of 0.97. The stock has a 50 day moving average price of $135.62 and a 200-day moving average price of $115.31. Masimo Co. has a 52-week low of $75.22 and a 52-week high of $196.83.

Masimo (NASDAQ:MASI) last announced its quarterly earnings data on Tuesday, February 27th. The medical equipment provider reported $1.25 EPS for the quarter, beating the consensus estimate of $0.82 by $0.43. The business had revenue of $548.90 million during the quarter, compared to analyst estimates of $545.69 million. Masimo had a return on equity of 13.77% and a net margin of 3.98%. The company’s revenue for the quarter was down 11.0% on a year-over-year basis. During the same quarter last year, the firm posted $1.32 earnings per share. As a group, equities research analysts anticipate that Masimo Co. will post 3.51 EPS for the current fiscal year.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.